Spyre Therapeutics Inc., a clinical-stage biotechnology company, announced on June 6, 2025, that its independent Compensation Committee has approved the grant of stock options to three non-executive employees. The inducement awards, granted under the company's 2018 Equity Inducement Plan, allow for the purchase of 50,200 shares of common stock at an exercise price of $15.40 per share, consistent with the closing price on June 2, 2025. These options come with a 10-year term and vest over a four-year period, beginning with one-fourth of the shares after the first year of employment, followed by monthly vesting of one-forty-eighth of the shares. These terms are contingent upon continuous service with Spyre.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。